Gain Therapeutics, Inc. (GANX), a clinical-stage biotechnology company, on Monday, announced the initiation of a Phase 1b clinical trial for its lead candidate, GT-02287, in individuals with Parkinson's disease, with or without a GBA1 mutation.
The company has received approval to begin enrolling participants for the trial in Australia, with enrollment expected to be completed by spring 2025. Data from the study is anticipated by mid-2025.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com